<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02931045</url>
  </required_header>
  <id_info>
    <org_study_id>KB/112/2016</org_study_id>
    <nct_id>NCT02931045</nct_id>
  </id_info>
  <brief_title>Antiplatelet Therapy Effect on Extracellular Vesicles in Acute Myocardial Infarction</brief_title>
  <acronym>AFFECT EV</acronym>
  <official_title>Antiplatelet Therapy Effect on Platelet Extracellular Vesicles in Acute Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Warsaw</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of Warsaw</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Platelet activation and aggregation leads to myocardial infarction. Platelet P2Y12 receptors&#xD;
      are essential for platelet activation. Antagonists against the P2Y12 receptor, which are&#xD;
      established in secondary prevention of myocardial infarction, have unexplained&#xD;
      anti-inflammatory effects. A novel P2Y12 receptor antagonist ticagrelor reduced&#xD;
      infection-related mortality compared to clopidogrel, previous standard treatment for patients&#xD;
      with myocardial infarction. Activated platelets release pro-inflammatory and procoagulant&#xD;
      platelet extracellular vesicles. The investigators assume that decrease in infection-related&#xD;
      mortality in patients treated with ticagrelor may be explained by greater inhibition of the&#xD;
      release of platelet vesicles by ticagrelor, compared to clopidogrel. This study is expected&#xD;
      to identify an additional mechanism of action of ticagrelor, which might contribute to the&#xD;
      observed clinical benefits in patients treated with ticagrelor.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 30, 2017</start_date>
  <completion_date type="Actual">December 30, 2019</completion_date>
  <primary_completion_date type="Actual">December 30, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Concentration of Platelet Extracellular Vesicles/ml</measure>
    <time_frame>6 months following the beginning of antiplatelet therapy</time_frame>
    <description>Concentration of platelet extracellular vesicles/ml measured with flow cytometry</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Concentration of Extracellular Vesicles Exposing Fibrinogen</measure>
    <time_frame>6 months</time_frame>
    <description>Concentration of extracellular vesicles exposing fibrinogen/ ml measured with flow cytometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of Extracellular Vesicles Exposing Phosphatidylserine</measure>
    <time_frame>6 months</time_frame>
    <description>Concentration of extracellular vesicles exposing phosphatidylserine/ml measured with flow cytometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of Extracellular Vesicles From Endothelial Cells</measure>
    <time_frame>6 months</time_frame>
    <description>The concentrations of extracellular vesicles from endothelial cells/ ml measured with flow cytometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of Extracellular Vesicles From Leukocytes</measure>
    <time_frame>6 months</time_frame>
    <description>Concentration of extracellular vesicles from leukocytes/ ml measured with flow cytometry</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Ticagrelor</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ticagrelor: oral, 180 mg once (loading dose) followed by 90 mg twice daily (maintenance dose)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clopidogrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clopidogrel: oral, 300 mg or 600 mg once (loading dose) followed by 75 mg once daily (maintenance dose)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor</intervention_name>
    <description>Comparison of ticagrelor with another antiplatelet drug (clopidogrel)</description>
    <arm_group_label>Ticagrelor</arm_group_label>
    <other_name>Brilique</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>Comparison of clopidogrel with another antiplatelet drug (ticagrelor)</description>
    <arm_group_label>Clopidogrel</arm_group_label>
    <other_name>Plavix</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Informed consent to participate in the study&#xD;
&#xD;
          -  Percutaneous coronary intervention with stent implantation due to first S T elevation&#xD;
             myocardial infarction, or first non S T -elevation myocardial infarction&#xD;
&#xD;
          -  Administration of a loading dose of clopidogrel&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known coagulopathy&#xD;
&#xD;
          -  Known history of bleeding disorder&#xD;
&#xD;
          -  Suspicion of intracranial haemorrhage&#xD;
&#xD;
          -  Need for oral anticoagulation therapy&#xD;
&#xD;
          -  Administration of glycoprotein (GP) II b - III a antagonists&#xD;
&#xD;
          -  Cardiogenic shock&#xD;
&#xD;
          -  Severe chronic renal failure (estimated glomerular filtration rate &lt; 30 mL/min)&#xD;
&#xD;
          -  Severe liver insufficiency&#xD;
&#xD;
          -  Chronic dyspnea&#xD;
&#xD;
          -  Increased risk of bradycardia&#xD;
&#xD;
          -  Autoimmune disease&#xD;
&#xD;
          -  Infectious disease&#xD;
&#xD;
          -  Neoplasms&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Study drug intolerance&#xD;
&#xD;
          -  Co-administration of ticagrelor or clopidogrel with strong CYP3A4 inhibitors&#xD;
&#xD;
          -  Participation in any previous study with ticagrelor or clopidogrel&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aleksandra Gasecka, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>1st Chair and Department of Cardiology, Medical University of Warsaw</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Laboratory of Experimental Clinical Chemistry, Academic Medical Centre of the University of Amsterdam</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1st Chair and Department of Cardiology, Medical University of Warsaw</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
    <country>Poland</country>
  </location_countries>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/29398917</url>
    <description>Related Info</description>
  </link>
  <reference>
    <citation>Gasecka A, Nieuwland R, van der Pol E, Hajji N, Ä†wiek A, Pluta K, Konwerski M, Filipiak KJ. P2Y12 antagonist ticagrelor inhibits the release of procoagulant extracellular vesicles from activated platelets. Cardiol J. 2019;26(6):782-789. doi: 10.5603/CJ.a2018.0045. Epub 2018 Apr 19.</citation>
    <PMID>29671861</PMID>
  </reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>October 10, 2016</study_first_submitted>
  <study_first_submitted_qc>October 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 12, 2016</study_first_posted>
  <results_first_submitted>August 18, 2020</results_first_submitted>
  <results_first_submitted_qc>November 28, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 23, 2020</results_first_posted>
  <last_update_submitted>November 28, 2020</last_update_submitted>
  <last_update_submitted_qc>November 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Warsaw</investigator_affiliation>
    <investigator_full_name>Aleksandra Gasecka</investigator_full_name>
    <investigator_title>Medical Doctor</investigator_title>
  </responsible_party>
  <keyword>extracellular vesicles</keyword>
  <keyword>inflammation</keyword>
  <keyword>thrombosis</keyword>
  <keyword>antiplatelet drugs</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The data will be presented in a collective form. If a particular study participant presents with an especially high or low concentration of the studied biomarker , the participant's characteristics may be described separately in a way which does not allow to identify the participant's personal data.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 21, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/45/NCT02931045/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ticagrelor</title>
          <description>Ticagrelor: oral, 180 mg once (loading dose) followed by 90 mg twice daily (maintenance dose)</description>
        </group>
        <group group_id="P2">
          <title>Clopidogrel</title>
          <description>Clopidogrel: oral, 300 mg or 600 mg once (loading dose) followed by 75 mg once daily (maintenance dose)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ticagrelor</title>
          <description>Ticagrelor: oral, 180 mg once (loading dose) followed by 90 mg twice daily (maintenance dose)</description>
        </group>
        <group group_id="B2">
          <title>Clopidogrel</title>
          <description>Clopidogrel: oral, 300 mg or 600 mg once (loading dose) followed by 75 mg once daily (maintenance dose)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                    <count group_id="B2" value="30"/>
                    <count group_id="B3" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                    <count group_id="B2" value="30"/>
                    <count group_id="B3" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Poland</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                    <count group_id="B2" value="30"/>
                    <count group_id="B3" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Concentration of Platelet Extracellular Vesicles/ml</title>
        <description>Concentration of platelet extracellular vesicles/ml measured with flow cytometry</description>
        <time_frame>6 months following the beginning of antiplatelet therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor</title>
            <description>Ticagrelor: oral, 180 mg once (loading dose) followed by 90 mg twice daily (maintenance dose)&#xD;
27 patients</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel</title>
            <description>Clopidogrel: oral, 300 mg or 600 mg once (loading dose) followed by 75 mg once daily (maintenance dose)&#xD;
28 patients</description>
          </group>
        </group_list>
        <measure>
          <title>Concentration of Platelet Extracellular Vesicles/ml</title>
          <description>Concentration of platelet extracellular vesicles/ml measured with flow cytometry</description>
          <units>Platelet Extracellular Vesicles/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2690000" lower_limit="1460000" upper_limit="4190000"/>
                    <measurement group_id="O2" value="4310000" lower_limit="2050000" upper_limit="6240000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Concentration of Extracellular Vesicles Exposing Fibrinogen</title>
        <description>Concentration of extracellular vesicles exposing fibrinogen/ ml measured with flow cytometry</description>
        <time_frame>6 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Concentration of Extracellular Vesicles Exposing Phosphatidylserine</title>
        <description>Concentration of extracellular vesicles exposing phosphatidylserine/ml measured with flow cytometry</description>
        <time_frame>6 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Concentration of Extracellular Vesicles From Endothelial Cells</title>
        <description>The concentrations of extracellular vesicles from endothelial cells/ ml measured with flow cytometry</description>
        <time_frame>6 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Concentration of Extracellular Vesicles From Leukocytes</title>
        <description>Concentration of extracellular vesicles from leukocytes/ ml measured with flow cytometry</description>
        <time_frame>6 months</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ticagrelor</title>
          <description>Ticagrelor: oral, 180 mg once (loading dose) followed by 90 mg twice daily (maintenance dose)&#xD;
27 patients&#xD;
One major bleeding event from the gynecologic tract</description>
        </group>
        <group group_id="E2">
          <title>Clopidogrel</title>
          <description>Clopidogrel: oral, 300 mg or 600 mg once (loading dose) followed by 75 mg once daily (maintenance dose)&#xD;
28 patients&#xD;
One major bleeding event from a diabetic foot ulcer</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>One major bleeding event from the gynecologic tract</sub_title>
                <description>In a patient who was eventually diagnosed with endometrial cancer.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>One major bleeding event from a diabetic foot ulcer</sub_title>
                <description>In a male patient who had dysregulated diabetes and infection of a diabetic foot.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Aleksandra Gasecka, MD, PhD</name_or_title>
      <organization>1st Chair and Department of Cardiology, Medical University of Warsaw</organization>
      <phone>+48225991951</phone>
      <email>alesandra.gasecka@wum.edu.pl</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

